CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).
Formulation
1 mg/ml in 1X PBS; BSA free, sodium azide free
Host
Mouse
Immunogen Region
Human full-length recombinant protein was used as the immunogen for this CEA antibody.
Isotype
Mouse IgG2a, kappa
Species Reactivity
Human
Note
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CEA antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Uniprot
P06731
Format
Purified
Purity
Protein G affinity chromatography
Storage
Store the CEA antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Applications
IHC-P
Description
Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT (1),Prediluted IHC only format: incubate for 30 min at RT (2)